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Abstract: In this work, we investigate the interaction of a nanoparticulate system for
nanomedicine applications with the biological environment, i.e., the human body. Following
the molecular communication paradigm, we assess how our nanoparticulate system model is
suitable for coexistence in a biological environment. Specifically, we assume the presence
of the human immune system that can affect the optimal behavior of nanoparticles, aiming
to locally deliver drug inside the human body. When a flow of nanoparticles is injected into
the blood, the interference due to the immune system can provide a strong decrease of the
nanoparticle concentration, by means of “humoral immunity”, the phagocytosis process, etc.
As a consequence, the correct drug delivery will occur with a lower probability. Since the
mechanism behind the biological immune system is very complicated, in this paper, we start
from a simplistic nanoparticulate model, where the nanoparticles and the cells of the immune
system are subject to the diffusion laws. Finally, we derive the end-to-end physical model of
our nanoparticulate nanomedicine system with the presence of the human immune system
cells. The error analysis is then investigated in terms of how these errors can affect the
performance of the system, i.e., nanoparticle survival probability.
Micromachines 2015, 6 1214
Keywords: nanonetworks; human immune system; fault probability; drug delivery
1. Introduction
In the past few years, nanotechnology has emerged as an evolution of technology enabling the design
of miniaturized nanoscale devices, i.e., nanorobots and nanoparticles. The behaviors and characteristics
of nanodevices distinguish them from the well-known features of devices at the macroscale level [1].
A nanodevice is the most basic functional unit, allowed to perform very easy tasks, like sensing or
actuation, due to the passive nature of these devices. A nanodevice is not just a device with reduced
size, but has unique properties of nanomaterials and nanoparticles, that have to be considered at any
level also from the security and privacy point of view, as envisaged in [2]; for instance, through the
functionalization process of nanosensors, it is possible to detect chemical compounds in concentrations
or the presence of different infectious agents, such as virus or bacteria [3]. In [4], quantum dots-DNA
(QDs-DNA) nanosensors based on fluorescence resonance energy transfer (FRET) are used for the
detection of the target DNA and single mismatch in the hepatitis B virus (HBV) gene.
Recently, research in the field of cancer diagnostics has made remarkable advances through the use
of nanotechnology for the development of nanoparticles, and it is possible to figure out the cooperation
among simple units in order to obtain globally-complex behavior [5]. Basically, gold nanoparticles and
near-infrared (NIR)-emitting semiconductor QDs are the most widely used, like in [6], where a campaign
of in vivo detection of cancer cells is carried out.
Electromagnetic fields and heat are largely used for sensing applications. Magnetic nanoparticles can
be used to selectively damage or kill cancer cells by heating them, since intracellular hyperthermia
has the potential to achieve localized tumor heating without any side effects [7]. Furthermore, by
functionalizing the nanoparticles with biological agents, such as antibodies or single-stranded DNA
chains, nanoparticles are forced to bind preferably to specific target cells.
A set of nanodevices, sharing the same medium (e.g., the human blood flow) and collaborating
on a common task (e.g., to deliver a drug concentration to a receptor), forms a nanonetwork [8].
Nanonetworks are expected to expand the capabilities of single nanodevices and then to enable new
nanotechnology applications in several fields.
Communication and signal transmission techniques occurring in nanonetworks are challenging
topics, due to the limited computation skill of nanodevices [9]. Molecular communication (MC) is
largely exploited for nanonetworks [8,10,11]. This is a novel communication paradigm, envisaged
as the most practical way in which nanorobots can communicate with each other by the use of
molecules as information carriers. Differently from electromagnetic waves providing electromagnetic
communication, or light waves in optical communication, or acoustic waves in acoustic communication,
in the MC paradigm, the information is encoded through the molecule presence (i.e., the presence or
absence of a selected type of molecule is used to digitally encode messages) [12], concentration [9,13],
configuration [14], etc.
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Following the MC paradigm, we consider a nanosystem where molecules (i.e., nanoscale particles)
transmitted by nanomachines (i.e., artificial devices), propagate in the medium following a diffusion
process and then arrive at the receiver, where ligand-receptor bindings eventually occur. Then, when
nanonetworks present therapeutic nodes (i.e., biological nanomachines), they are called as body area
nanonetworks (BAN2), aiming to empower sophisticated nanomedicine applications [10]. A similar
work [15] considers the transmitter and the receiver as a drug injection, and drug delivery, while the
channel is realized by the transport of drug particles. The authors assume an MC channel as two separate
contributions, namely the cardiovascular network model and the drug propagation network.
Several works dealing with drug delivery applications via nanoparticles have been proposed. In [16],
Felicetti et al. present a communication protocol between a pair of biological nanomachines, built upon
the MC paradigm in an aqueous environment for drug delivery applications. Analogously, in [17],
bio-nanomachines are assumed as senders that transmit molecules, as well as receivers that chemically
react to the molecules propagating in the environment.
In this work, we assume that nanoparticles are transmitted by nanomachines and propagate in the
medium following a diffusion process, until reaching the receiver, by considering the same principles of
molecular communication [18]. Since the nanoparticles are accordingly functionalized, they can form
bindings with specific receptors, whenever available. However, in real scenarios, the emission, diffusion
and reception processes can show different behaviors. For example, many biomedical applications
require a multi-source emission of nanoparticles, where each source (i.e., each nanomachine) can emit
a nanoparticle flow. As a consequence, synchronous and asynchronous nanoparticle emission can affect
the diffusion process, and degrade network performance (i.e., with an increase of interference and
nanoparticle collisions).
The increasing exposure of nanotechnology to humans has generated the need to analyze the impact
of nanoparticles on the human immune system of the hosting body. In fact, the immune system plays
a vital role in human beings’ health, since it is generally thought to protect against external invaders,
such as bacteria, viruses and other pathogens, while ignoring itself. This task is accomplished by
means of the phagocytosis process (i.e., a major mechanism used to remove pathogens). In biological
environments, the presence of the immune system could affect the behavior of the diffusion and reception
of nanoparticle flows [19,20], and it needs to be deeply analyzed and studied in order to avoid undesirable
side effects.
In the last few years, there has been an increased interest in studying the effects and interactions
of the metal-based nanoparticles with the immune system. In [21], the authors focus on metal-based
nanoparticles and analyze how metals affect the immune system, based on the different physical and
chemical properties that induce different types of responses of the cells. The responses and the effect are
analyzed by starting from considering the different types of specific cells of the immune system.
In [22], the authors focus on the effect of silver nanoparticles on the immune system by analyzing
the interaction between silver nanoparticles with viruses, bacteria, etc. In [23], Felicetti et al. provide a
software platform, named BiNS2, able to simulate diffusion-based molecular communications inside
blood vessels, in order to analyze the interactions of nanoparticles with the blood cells. The same
simulator is also exploited in [24], where the authors describe a specific communication process
happening inside blood vessels, atherogenesis. Another similar paper is [25], where a particle-cell
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hybrid model is developed to model nanoparticle transport, dispersion and binding dynamics in the
blood. Finally, the authors in [26] focus on the interference aspects of the gold nanoparticles with the
macrophage cells studied through a specific approach with microscopy techniques based on electrons
and ions.
A different perspective of the interaction between the immune system and the nanoparticles is given
in [27], where the authors regard the intravenous administration as a potential “natural” targeting to be
improved. The scope is to achieve an optimal delivery to immune cells.
The interaction between iron oxide (IO) nanoparticles and the immune system is investigated
in [28], by specifically evaluating their effect on nanoparticle bio-distribution and tumor targeting.
Landsman-Milo et al. [29] focus on lipid-based nanoparticles (LNPs) and study their capability and
potentiality as carriers for drug. They analyze how the LNPs interact with different subsets of leukocytes,
and they also give detailed examples of the suppression or activation of the immune system by the use
of LNPs as drug deliverers.
Another issue exists at the receiver side, where a selective reception of nanoparticles occurs (i.e.,
a given nanoparticle can form a complex only with the “corresponding” receptor). Finally, once the
nanoparticles arrive at the receiver, they are bound, and the detection process can occur.
In this paper, we investigate and analyze the behavior and interactions of the immune system in a
biological environment, with one or more flows of nanoparticles emitted for nanomedicine purposes (i.e.,
drug delivery applications). Under the assumption that the main cells comprising the immune system
(i.e., the B-cells) are comparable, in terms of size, to the flows of nanoparticles emitted, we consider
a very simple model for the immune system. Then, we can assess how the immune system affects the
diffusion and reception of nanoparticles. Specifically, we assume that receptors on the surface of B-cells
chemically react with nanoparticles. This happens for antigens (in this case, nanoparticles) for which
B-cells have antibodies; then, B-cells recognize nanoparticles as “invaders”, and this should trigger their
production of antibodies. The characterization of the end-to-end physical model permits performing a
detailed analysis of the errors that can occur during the diffusion process and that impact the performance
of the system, expressed in terms of nanoparticle survival probability. This latter term here is used as a
kind of measure of the percentage of drug correctly delivered with respect to the amount immersed in
the medium through the nanoparticles. The simplified immune system model that we consider in this
paper allows the treatment of B-cells similarly to nanoparticles, which compete with the nanoparticles
for the medium.
The remainder of this paper is organized as follows. The modeling of the human immune system
as a network with active molecules (i.e., the B-cells) is described in Section 2. A simple yet effective
model for the immune system has been assumed in this paper, so that we can observe the interactions
that occur among nanoparticles and B-cells. In Section 3, we discuss the physical end-to-end model
for one nanoparticle flow emitted by a nanomachine, toward a receiver. We describe how nanoparticles
diffuse in the biological environment, where the presence of B-cells can cause interferences and then a
reduction of the nanoparticle flow reaching the receiver (e.g., a diseased biological tissue). We assume
the nanoparticles [30] as carriers of the nanonetwork that are transmitted, diffuse and finally reach
a receiver nanomachine. Those processes can be affected by the reaction of the immune system to
the presence of nanoparticles, then causing nanoparticle loss and errors in the diffusion and reception
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processes, respectively. For completeness, a multi-nanomachine source scenario in synchronous and
asynchronous emission mode is then assumed. The main errors occurring along the biological channel
are investigated in Section 4, where we assume that nanoparticles can be affected by two types of errors
(i.e., lost and interfering nanoparticles). A model describing the nanoparticle errors is then presented.
We also introduce the concept of hazardous misleading information (HMI) in Section 5. In Section 6,
we briefly revise some representative contributions to the interactions between the immune system and
nanoparticles. Finally, conclusions are drawn at the end of the paper.
2. Modeling of the Human Immune System
The immune system aims to protect the biological environment, against external invaders (i.e.,
pathogens). It is organized as a network of lymphocytes and antibody molecules that interact via specific
processes (e.g., phagocytosis).
The role of idiotypic networks [31] in the operation of the immune system has been investigated
by a number of mathematical models [32–35]. The immune system operates as an interconnected
network that is very complex and difficult to realize through experiments. Sometimes, scientists
perform experiments with a few cell types, in order to obtain some useful information about isolated
interactions. It is clear that this kind of experiment can be useful in some ways; however, it isolates
the immune cells from the natural context of a very large biological network, and this can lead to a
non-physiological behavior.
On the other side, in vivo experiments allow considering and observing the phenomena in their
physiological context. However, by neglecting the various difficulties related to this kind of experiment,
the results are derived from the global behavior, and it is difficult to fix the individual components.
This represents a very relevant gap in terms of immune system knowledge, but it can be bridged by
mathematical modeling.
Based on the taxonomy presented in [36], we can classify the modeling of immune systems in the
following five categories:
• Ordinary differential equations (ODE): this type of model is the most common and has been used
for cancer immunology;
• Delay differential equations (DDE): these are infinite-dimensional dynamical systems, and they
require more computational capabilities and more complexity, from an analytical point of view,
than finite dimensional-based modeling, like ODE;
• Partial differential equations (PDE): these are able to capture more complex features than ODE
and DDE. This category is usually applied as an age-structured model, which considers the
progression of individual cells via a scheduled development process. It can also be applied as a
spatio-temporal model. Based on this approach, in [37], the authors represented the simulation of
two chemical signals that interact as antagonist by allowing neutrophilsto orient themselves based
on the chemical gradient. Their PDE model is represented as a diffusion system with chemotaxis
equations in one dimension;
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• Stochastic differential equations (SDE): these are written in a similar way as ODE, but their
variables can assume random values. Through SDE, it is possible to take into consideration the
noise and other sporadic events modeled as Poisson processes;
• Agent-based models (ABM): these models refer to a totally different way of characterization
with respect to differential equation systems. In ABMs, there are distinguishable agents (i.e.,
molecules or cells), while the differential equation-based models deal with a collective population
(i.e., cell densities). ABMs allow taking into account the probabilistic uncertainty related to the
biological interactions.
Leveraging this classification, a spontaneous question related to all of the possible models available is
how to select the most appropriate and suitable one. The models present different levels of complexity,
and this could be a selection criterion, then justifying the enormous success of ODE models, which
are adopted to represent also complex biologic systems without requiring too much computational
complexity. On the other hand, ODE models are not effective whenever it is necessary to include the
spatial distribution of molecules.
In any case, the right way to select the most appropriate model is based on the analysis of the
requirements related to the specific application and context considered. This is exactly what we
realized in this work. Specifically, we started from the consideration that a certain amount, a density,
of nanoparticles is injected in the blood, and we need to model the immune system by considering
both spatial-temporal dynamics and the progression of individual nanoparticles. In this way, we take
into account (i) the evolution process (nanoparticles diffuse and interact with B-cells) of nanoparticles
and (ii) their associated desired functionality of death, in order to be absorbed through the normal
biological process.
In this sense, a considerable amount of work has arisen around a model, namely the B-cell
model [32–34]. It includes only B-cells and attempts to describe the population dynamics of a set of
n distinguishable B-cell clones that interact in a network. The B-cell model has been thoroughly studied
for the case of two B-cell clones (n = 2) [38]; however, when a large number of clones are present,
the model relies on the replicator equation model [39]. In order to capture all of the key features that
characterize our system, we consider a PDE model, and more specifically, we make reference to the
B-cell model.
Let yk denote the concentration of the k-th B-cell clone (i.e., with k = {1, . . . , n}) and c be the total





from which the relative concentrations of the clones will be derived as xk = yk/c. When stimulated by
interactions with other clones, a clone will proliferate. It is possible to summarize the effects of all other







b̃kjxj = c · hk (x) (2)
where the coefficients b̃kj describe the topology of the B-cell network.
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In the B-cell model [38], the population dynamics of B-cell clones are described by:
ẏk = yk
[
pf̃ (hk (y))− d̃k
]
+ s̃k (3)
where p is the proliferation rate, f̃ is a response function determining the fraction of cells proliferating, d̃k
is the death rate of the k-th clone and s̃k is the (constant) influx of the k-th clone from the bone marrow.
Notice that the influx rates are typically small (i.e., assumed as zero), and they can be reintroduced
as perturbations of the simplified dynamical system with s̃k = 0. Further, we assume that the death




pf̃ (hk (y))− d̃
]
(4)
The rate of proliferation of B-cells in response to the field that they experience is determined by the
response function f̃(h). The response of B-cells to a ligand (i.e., an antigen that interacts in a specific
manner with the receptors on the cell’s surface) is typically unimodal [40]; then, small concentrations of
ligands give little or no response, and there is an optimal concentration that gives a maximal response.
It is worth noticing that the B-cell model as exposed in this paper can be easily generalized to take
into consideration the general proliferation of white blood cells. In order to prove that, let us introduce





where a is the proliferation rate, y is the current density of the circulating white blood cells, yτ = y(t−τ)
is the density τ time units in the past and b is the destruction rate (or death rate).





where it is worth recalling that f̃ represents the response function determining the fraction of cells
proliferating, we obtain Equation (4).
3. Physical End-to-End Model
In this section, we present the physical end-to-end model of the emission, diffusion and reception of
nanoparticles, assumed to be introduced into the human body (e.g., via injection). In this model, we
rely on well-known Fick’s laws of diffusion and the assumption that a nanoparticle can be captured and
bind with a receptor. We also exploit the B-cell model by assuming one B-cell flux interacting with a
concentration of nanoparticles.
Similarly to [42], we consider a single nanoparticle as an indivisible object, released to (during the
emission process) or collected from (during the reception process) a position in the space S, by means
of chemical reactions. In the diffusion process, nanoparticles are free to move into the space following
the laws of diffusion of particles in a flow. Figure 1 depicts a schematic of the end-to-end model in
a biological environment, where a transmitting nanomachine emits a flux of nanoparticles toward a
receiver. Notice that the receiver modeling is not addressed in this paper, since the aim is the modeling
of the human immune system and how it affects the nanoparticulate drug delivery system.

















Figure 1. End-to-end physical model in the biological space S, linking a transmitting
nanomachine to a receiver. One or more fluxes of nanoparticles are emitted by the transmitter
and diffuse along the propagation channel. The presence of B-cells causes a reduction of
the nanoparticle concentration able to reach the receiver, modeled as fixed nodes in the
nanonetwork. Moreover, lost and interfering nanoparticles can provide errors during the
reception process (i.e., no reception and missing reception, respectively).
The nanomachine is provided with several apertures from which the nanoparticles are emitted. The
overall nanoparticle concentration flux emitted by the nanomachine is stimulated by a concentration
gradient between cout and cin, which represent the nanoparticle concentration value outside and inside the
nanomachine, respectively. Specifically, the particle concentration inside the nanomachine is triggered
according to increases (decreases) of the input signal, which allows the transmitter to increment (reduce)
cin, and then, the particle concentration at the output cout is increased (decreased), as well. Notice that
we assumed only a positive nanoparticle rate modulation, i.e., cin < cout, [43].
A single nanoparticle is functionalized to be captured by a receptor, by means of chemical reactions.
When captured, the reception process allows decoding the information within the nanoparticle (e.g., the
drug concentration).
In the space S within the biological environment, we assume the presence of B-cells, which can
recognize neighboring nanoparticles as antigens and then will try to defeat them (i.e., interference
nanoparticle/B-cell). Finally, along the biological channel, we consider the presence of errors, expressed
in terms of lost and interfering nanoparticles.
The overall nanoparticle concentration flux JT (x, t) is given by the sum of the N nanoparticle
concentration gradients i.e., withN as the number of apertures of the nanomachine, at time t and position
x through Fick’s first law (we recall that ∇ is an operator used in vector calculus as a vector differential
operator), as follows:
JT (x, t) = −D
N∑
i=1
∇Ci,NP (x, t) (7)
and at the transmitter side (i.e., at position x = xT (nm) and time instant t = t0 (ns), it becomes:
JT (xT , t0) = −D
N∑
i=1
∇Ci,NP (xT , t0) (8)
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where Ci,NP (x, t) (mol/cm3) is the i-th nanoparticle concentration with i = {1, 2, . . . , N} andD (cm2/s)
is the diffusion coefficient, assumed as a constant value for a given fluidic medium and depending on
the size and shape of nanoparticles, as well as the interaction with the solvent and viscosity of the
solvent. Notice that the nanoparticle transmission rate rT (t) can be identified with Equation (8), due to
the dependance on the concentration gradient.
Unfortunately, Fick’s first law works when applied to steady-state systems, namely the concentration
will keep constant both along space and in time. However, since nanoparticles diffuse along space, the
concentration changes during time, and they determine different levels of concentration. Then, we can







where CNP is the nanoparticle concentration as emitted by the transmitter.
During the diffusion process, we consider that the nanoparticles encounter the B-cells. Due to
comparable sizes, we can model the B-cells by means of Fick’s first and second laws, as considered
for the nanoparticles. Under this assumption, the interactions among B-cells and the nanoparticles can
occur, thus affecting nanoparticle flows. Indeed, analogously to Equation (8), we can model the B-cell
concentration flux JB(x, t) as a unique contribution, which is expressed as:
JB (x, t) = −DB∇CB (x, t) (10)
where CB(x, t) is the B-cell concentration at position x and at time t and DB (cm2/s) is the diffusion
constant for the B-cells (i.e., with DB 6= D). Furthermore, from Equation (11) we can derive the B-cell







Due to the phagocytosis process of the immune system, the B-cell flux interacts with the nanoparticles,
thus providing a reduction of nanoparticle concentration flux. The interaction among B-cells and
nanoparticles allows writing the following:
J[T+B] (x, t) =



















with QNP/B as the initial concentration of nanoparticles and B-cells, respectively. Equation (12)
represents the nanoparticle concentration flux after the phagocytosis process, and it can be rewritten as:
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When considering the circulatory system, it is more appropriate to consider a model that takes into
account drift into the diffusion process. Let us suppose that the fluid is flowing with a constant drift
velocity v (i.e., v > 0); the diffusion equation in the medium would be:






where we consider that the pdf of the position of a single particle, for every t, has a Gaussian
distribution, i.e.,






However, it is worth noticing that the basic model (namely, without the drift) has been considered as
the reference model for developing a future in vitro experiment to validate our interference system.
Figure 2 depicts the concentrations of nanoparticles and B-cells, occurring along space, by assuming
the nanoparticles are emitted in position xT = 0 (nm), while the B-cells in position xB = 99 (nm). The
flows diffuse in the opposite direction, i.e., from left to right for the nanoparticles and from right to left
for the B-cells. Different curves are for different values of QNP/B, specifically for QNP/B = 300 (mol)
(solid lines) andQNP/B = 1000 (mol) (dotted lines). Numerical values are chosen as a practical example.






























Figure 2. Variation of nanoparticle and B-cell concentrations vs. space and for different
values of initial concentration QNP/B.
The interaction among nanoparticles and B-cell vs. space is shown in Figure 3a, where we observe
how the flow of nanoparticles decreases due to the response of the immune system that recognizes the
nanoparticles as invaders.
We assume the nanoparticles move at 1.13 × 103 (nm2/s) and the B-cells at 16.21 (nm2/s). Those
values have been obtained based on the well-known formula of the diffusion coefficient that is related to
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where kB is the Boltzmann constant equal to 1.38×10−23J/K, T is the temperature expressed in Kelvin,
η is the viscosity of the liquid (m Pa ·s) and d is the size of the nanoparticles (B-cell) in (nm) (in (µm),
respectively). Specifically, we assumed that the liquid is at the temperature of 37 ◦C and the viscosity of
the blood is 4.0 (m Pa ·s).
After the phagocytosis process, the percentage of nanoparticles able to reach the receiver (i.e.,
NP + B-cell flow) will be lower than that in the case of no response of the immune system (i.e., NP
flow). Indeed, if in space the concentration of B-cells is low (i.e., approximable to zero), there will
be no response of the immune system and then no decrease of the nanoparticle concentration. Finally,
Figure 3b depicts the dynamic behavior of the nanoparticle flow vs. space, when affected by the B-cell
concentration (i.e., after the phagocytosis process). We observe a decrease of nanoparticle concentration
flow due to the response of the immune system. This shows that in a real scenario, during the diffusion
process, the nanoparticle concentration flow does not follow an ideal behavior, but is affected by other
molecules (i.e., the B-cells), which destroy the nanoparticles, since they are recognized as pathogens.












































Figure 3. Variation of nanoparticle and B-cell concentrations vs. (a) time and (b) space
for different values of initial concentrations, i.e., QNP = 1000 (mol) and QB = 300 (mol).
We assumed specific sizes for nanoparticles and B-cells. The superposition effect provides
the average concentration due to the interaction among nanoparticles and B-cells (i.e.,
NP + B-cell).
3.1. Multi-Source Nanoparticulate Scenario
After describing the behavior of B-cells when a single-source nanoparticle flow is injected into the
human body, we analyze a multi-source scenario, considering the emission of two nanoparticle flows at
different diffusion coefficients. This particular scenario represents the case of the injection of different
nanoparticles flows for therapeutic applications.
Figure 4a depicts the concentration behavior for two flows of nanoparticles (i.e., NP1 and NP2)
moving at 1.41 × 103 nm2/s and 1.13 × 103 nm2/s, respectively. Again, we assume the B-cells diffuse
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at 16.21 nm2/s. We then evaluated the immune system response, computed as the average trend given
by the two nanoparticle flows and the B-cells. This response is then assessed versus space in Figure 4b.
Similarly to Figure 2, we observe that the nanoparticle flows (i.e., red and blue lines) diffuse in opposite
directions, and the immune system response (i.e., black line) is almost null along the end-to-end distance
from the transmitter at 0 nm to the receiver laying at 99 nm.























NP1 + NP2+ B-cell
(a)






















NP1 + NP2 + B-cell
(b)
Figure 4. Variation of nanoparticles and B-cell concentrations, vs. (a) time and (b) space
for different values of initial diffusion coefficients i.e., 1.41 × 103 (nm2/s) for NP1,
1.13 × 103 (nm2/s) for NP2 and 16.16 (nm2/s) for B-cells. The superposition effect provides
the average concentration due to the interaction among two flows of nanoparticles and the
B-cells (i.e., NP1 + NP2 + B-cell).
The concept of synchronous and asynchronous nanoparticle emission takes place when adopting a
multi-source nanoparticle scenario. In the case of asynchronous nanoparticle emission, we assume the
emission of NP1 nanoparticle flow starts at t = t1 s, while NP2 nanoparticle flow starts at t = t2 s with
t2 > t1. As a consequence, the resulting flow JNP(x, t) is given as the sum of the two single flows,
such as:
JNP(x, t) = JNP1(x, t) + JNP2(x, t) (19)
Figure 5a depicts the concentration trend in the case of asynchronous nanoparticle emission versus
time, where the initial concentrations are the same (i.e., Q = 1000), and the diffusion coefficients for
NP1 and NP2 flows are respectively 2 and 0.18 (nm2/s). On the other hand, Figure 5b shows the emission
of NP1 and NP2 nanoparticle flows in synchronous mode, where the resulting flow JNP(x, t) is given as
the average of the two single flows, such as:
JNP(x, t) =
JNP1(x, t) + JNP2(x, t)
2
(20)
In this case, the nanoparticle emission occurs in the same time instance, and it results as the emission
of a single flow obtained as the average of JNP1 and JNP2 .
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Figure 5. Nanoparticle concentrations for two flows NP1 and NP2 emitted in (a)
asynchronous and (b) synchronous mode. The resulting concentrations are depicted in black.
4. Nanoparticle Errors
Apart from the presence of B-cells that can cause a reduction of nanoparticle concentration, we can
distinguish other errors occurring in our nanoparticulate system during the diffusion process, namely (i)
the interfering nanoparticles, i.e., nanoparticles that can approach the receiver, but are not able to form
bindings and cause interference and (ii) the lost nanoparticles, i.e., nanoparticles that are not able to
reach the receiver, since they are lost during the diffusion process.
Interfering nanoparticles provide an increase of the noise level in the channel, causing a missing
reception, since they can lay very close to the receiver, then obstructing other nanoparticles from the
correct capture at the receptor. In this context, a missing reception means that a nanoparticle lays very
close to the receptor, but is not bound. On the other side, lost nanoparticles will never reach the receiver
and then will provide no reception, since no correct nanoparticle capture will occur. In this context, no
reception means that a nanoparticle will never form a binding, since it will not reach the receiver.
Based on such errors, we can distinguish two kinds of events, such as (i) the individual and correlated
simultaneous nanoparticle faults and (ii) the interference-based nanoparticle faults. In the case of
individual nanoparticle faults, at least one nanoparticle out of a nanoparticle flow is affected by noise,
and then, the nanoparticle reception at the receiver can be corrupted. Finally, the case of correlated
simultaneous nanoparticle faults represents the extension of individual faults, since it assumes errors
correlated among multiple nanoparticle flows.
4.1. Individual and Correlated Simultaneous Nanoparticle Errors
We can define p as the probability of having one failed nanoparticle, i.e., NPf = 1 (specifically, one
lost nanoparticle), out of NNP nanoparticles, whose expression is:
p[NPf = 1] ∼= NNP · PNPf , with PNPf  1 (21)
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where PNPf is the rate of nanoparticle faults. It follows that the probability p of having two failures out
of NNP nanoparticles is:





P 2NPf · (1− PNPf )
NNP−2 (22)
and then, the probability of having three or more failures is:
p [NPf > 2] =
NNP∑
l=3
P lNPf · (1− PNPf )
NNP−l (23)
As an example, for PNPf = 10−6, we obtain p [NPf = 2] = 0.183 in the case of NNP = 106, while
the probability decreases (i.e., p [NPf = 2] = 0.0023) in the case of NNP = 107. Figure 6 depicts the
nanoparticle fault probability for different values of fault probability of a single nanoparticle out ofNNP ,
for NNP = [106, 107, 108].




















Figure 6. Probability of having two failed nanoparticles out of a flow of NNP = 106
(asterisk), NNP = 107 (circle) and NNP = 108 (upward-pointing triangle).
Notice that it is realistic to assume that the probability of correlated simultaneous nanoparticle faults
(i.e., PcNPf ) can exceed the individual fault probability (i.e., PsNPf ). On the other hand, when m
nanoparticle flows are considered, the probability that at least one flow is not affected by a correlated
failure (i.e., mhealthy ≥ 1) is:
Pr {mhealthy ≥ 1} = 1− PmcNPf (24)
Thus, for PcNPf = 10−6 with m = 3 nanoparticle flows, the probability that at least one flow is not
affected by correlated faults is less than (1− 10−18).
4.2. Interference-Based Nanoparticle Faults
This case occurs due to interference errors along the channel from the transmitter to the receiver.
When the nanoparticles diffuse, an additional delay can happen, mainly due to the presence of obstacles
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in a lattice, i.e., a three-dimensional space. This corresponds to the nanoparticle to “surf” in a perpetual
way until this is eliminated by the human body. In this case, a missing reception can still arise due to
large random errors produced during the reception process (i.e., interfering nanoparticles that are laying
near the receptors, but that are not bound). Indeed, a great part of the desired particles will not be able
to reach the surface receptors of the receiver node, and at the same time, the interfering particles will not
be compatible with the surface receptors. Then, there will be no reception. However, besides their small
probability of occurrence, interfering nanoparticles can cause a missing reception, due to the very short
proximity of these nanoparticles to the receptors.
Let us denote with PsNPf the probability of the fault of a single nanoparticle and with NNP the
number of nanoparticles available at the end of the diffusion process. The probability p that none of
them is affected by a fault (i.e., the nanoparticles can form bindings and are not interfering) is bounded
by the probability that none of them is affected by an independent fault, i.e.:
p ≤ (1− PsNPf )NNP (25)
In practice, for PsNPf  1, the following approximation holds:
p ≤ 1−NNP · PsNPf (26)
We need to compute the conditions under which this approximation is true. In order to do that, we
will derive a free boundary problem for the associate Fokker–Planck partial differential equation, which
is derived from the calibration of the barrier function [44].
Let us define the function PsNPf (t) as the probability that a single nanoparticle has faulted by time t,
and P ′sNPf (t) as the fault probability density. Then, the probability of fault between t and (t + ∆t) can
be represented as P ′sNPf (t)∆t, as seen at time t = 0.
By considering W (t) as a standard Wiener process, we can associate the nanoparticle concentration
process as an Ito process [45]X = {Xt, t ≥ 0}(t), withXt=0 = X0. The reasons for which we associate
an Ito process to our system is that an Ito process is a stochastic process that can be expressed as the sum
of an integral with respect to Brownian motion and an integral with respect to time, as shown in:
Xt = X0 +
t∫
0
a (Xs, s) ds+
t∫
0
b (Xs, s) dWs, t ≥ 0 (27)
whereX0 is a scalar starting point and {a (Xt, t : t ≥ 0)} and {b (Xt, t : t ≥ 0)} are stochastic processes
satisfying certain regularity conditions. The terms a (Xt, t) and b (Xt, t) are the drift and the diffusion,
respectively. A solution of Equation (27) is:
dXt = atdt+ btdWt (28)
where at = a (Xt, t) and bt = b (Xt, t). Equation (28) represents the expression of Brownian motion with
an instantaneous drift at and an instantaneous variance b2t of diffusion. The faults of the nanoparticles at
time t are expressed through:
X (t) = b (t) (29)
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with the assumption that X (t− 1) > b (t− 1), where b(t) represents the barrier function related to the
density of nanoparticles present in the solution.
Let us call τ the first time that X(t) hits its barrier, then:
τ = inf {t ≥ 0 : X (t) ≤ b (t)} (30)
By calling PS(x, t) the survival probability density function of X(t), we have:
PS (x, t) dx = Pr [x < X (t) < x+ dx, τ ≥ t] (31)
for x ≥ b(t). Then, by applying the results known in the theory of probability, the function PS(x, t) in






∆PS (x, t) +
F (x)
γ




= D is the diffusion coefficient, γ is a viscosity coefficient and F (x) is a strength field. From
Equation (25), we can define the survival probability up to time t corresponding to (1− PsNPf (t)) and
calculated by integration as:
1− PsNPf (t) =
∞∫
b(t)
PS (x, t) dx (33)
so that the fault probability PsNPf (t) is related to the survival probability density function PS(x, t) and
the barrier b(t) through the following equation:
PsNPf (t) = 1−
∞∫
b(t)
PS (x, t) dx (34)
Since the pair {PS(x, t), b(t)} has to be consistent with the fault probability {PsNPf (t); t > 0}, the
barrier b(t) has to be chosen in an appropriate fashion. This is clear by differentiating the fault probability
with respect to time in Equation (34):













In practice, the survival density function has to satisfy both Condition (33), and a boundary condition
at the barrier x = b(t). This implies a free boundary problem for the forward Fokker–Plank equation,
since the boundary b(t) is not known and the choice of its value has to be consistent with the boundary
Conditions (33) and (35). Notice that the derived model is invariant with respect to transformation as
scaling. Indeed, by introducing s0 as a positive number and transforming x̃ = x/s0, b̃ (t) = b/s0 and
ã (x̃, t) = a (x, t) /s0, then the new function can be written as:
P̃S (x̃, t) = s0PS (x, t) (36)
that satisfies Equations (32)–(35). Finally, if s0 is a constant value, i.e., (s0 = 1), the fault index is taken
to be a standard Brownian motion. On the other side, if s0 is not constant, we can also take into account
the index as time.
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From the navigation theory [46,47], we take the concept of protection level [48] and adapt it to our
system. Specifically, we assume it as the event that there is at most one in ten million chance that the
detection error is greater than the protection level (PL). The intention behind this is to keep the probability
of hazardous situations (i.e., faulty nanoparticles) extremely low. Indeed, when every nanoparticle is
healthy, denoting by σ2d the variance of the detection error, modeled as a Gaussian random variable (r.v.),
and η its expectation, then the conditional probability of a misleading information (MI) event, given a
missing alert (MA) event, equals the probability that the detection error ∆E will exceed the protection
level PL. Basically, we obtain:
























5. Hazardous Misleading Information Rate
After describing all of the cases for nanoparticle errors, we can now derive the hazardous misleading
information (HMI) rate. Again, from the navigation theory, we use the concept of the HMI event that
occurs when the detection error exceeds the alert limit, i.e., for a given parameter measurement, the alert
limit is the error tolerance not to be exceeded without issuing an alert. In our case, the alert represents
the event that a nanoparticle is considered healthy while it is not. This kind of analysis will be very
useful in order to characterize the different types of misleading information and o analyze their effect on
the whole system.
Let us denote by PNPHMA the missing alert probability when all of the nanoparticles of a given flow
are healthy and PNPFMA as the missing alert probability when at least one nanoparticle of a given flow is
faulty. Notice that the acronyms MA, MI , NPH and NPF are given in Table 1. Moreover, PNPHMI/MA is
the conditional probability of an MI event given an MA event, when all of the nanoparticles of a given
flow are healthy and PNPFMI/MA the conditional probability of an MI event given an MA event when at
least one nanoparticle of a given flow is faulty. Then, NDec is the number of independent decisions in a
given time interval, i.e., one hour [49]. PNPH is the probability that all of the nanoparticles are healthy,
and PNPF = 1− PNPH is the probability that at least one nanoparticle is faulty.
Then, the hazardous misleading information rate RHMI is evaluated as the probability of an HMI




]NDec · PNPH + [1− PNPFMI/MAPNPFMA ]NDec · PNPF} (39)
Roughly speaking, the hazardously misleading information (and then, the computation of the rate
of the probability of the hazardous misleading information) will give important information about the
integrity requirements of the system. Based on the different potential applications in nanomedicine, the
“integrity” definition could assume different values, but in any case, it would represent a very important
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point to be fixed. Notice that, in principle, the integrity risk [50] is proportional to the square of the
bias introduced by the nanoparticle failure. Thus, the hazardous misleading information rate should be
averaged even with respect to this quantity. However, since a reliable statistical model for the entity of
the errors caused by nanoparticle failures is not available, the protection level should be set in accordance
to the worst case.
Table 1. Acronyms used for the computation of the hazardous misleading information
(HMI) rate.
Acronym Event Type
MA Missing alert event
MI Misleading information event
NPH Event corresponding to healthy nanoparticles
NPF Event corresponding to one or more uncorrelated nanoparticle failure
6. Related Work
One major obstacle for the use of nanoparticles in in vivo applications is the rapid clearance by the
cells of the immune system. Several contributions have tried to address the issue of the interaction
between the nanoparticulate system and the immune system. In [22], the authors outline the importance
to avoid extensive immunostimulatory or immunosuppressive reactions to the nanomaterials when
injected in the body.
A deep comprehension of the interactions among the two systems, namely the nanoparticulate and
the immune one, would be very useful to decree the success of nanomedicine. In order to study
this specific aspect, the authors in [22] focus on Ag nanoparticles. In [51], the authors focus on the
observations related to two specific immune correlated “activities”, such as immunostimulation and
immunosuppression. They consider that particle properties may generate specific interactions with the
immune cells.
An initial study on the phagocytosis effect of immune cells has been done in [52]. The authors
show how different properties can “stimulate” different responses and also have an impact on the
biodistribution of the nanoparticles. They provide an overview of in vitro methods, useful in identifying
interactions with the components of the immune system, and in particular, they focus on the nanoparticle
distribution to tissues based on the effect of this type of interaction. The aim of the authors is very
similar to our scope, but we approached it in a different way, since we rely on a general and a
theoretical/statistical model.
Furthermore, in [53], the authors focus on the phagocytosis system and outline specific approaches,
such as grafting polyethylene glycol onto particles (PEGylation), which may increase the survival or
circulation time in the blood for the nanoparticles. The authors outline these nanoparticles as being still
cleared, and the processes behind this clearance are not completely understood. They study different
strains that can impact on the rate of clearance and identified the differences in nanoparticle clearance
when different strains of mice were considered.
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An interesting summary of the interaction between the immune system and metal-based nanoparticles
is reported in [21], where the authors conclude that the interaction of nanomaterial with the immune
system is attracting much attention, since the physicochemical properties of nanoparticles are of
paramount importance for the immunological response. On the other side, differently from the
contributions considered, in this work, we try to design a quite general and yet complex model that
can be effectively used and exploited for inferring interesting information regarding the nanoparticulate
clearance ratio.
7. Conclusions
In this paper, we analyzed the interaction of the human immune system with a nanoparticulate system
by deriving the errors (i.e., lost and interfering nanoparticles) and the cases of misleading information.
The human immune system is very complex, and the approach we considered in this work was a
simplified mathematical model based on differential equations including also B-cells, in order to make
the system as realistic as possible. The choice of the specific model was also “constrained” by the
necessity to include spatio-temporal features of the immune response and the maturation process of the
B-cells that compete with the nanoparticles to share the biological environment.
This specific analysis allows us to treat the cells deriving from an immune response as a kind of
interferent. We derived the probability analysis for the cases of missing and no reception on the basis of
the presence of nanoparticle errors (i.e., interfering and lost nanoparticles). Moreover, we also derived
the analysis of misleading information by considering different types of events.
As future work, we aim to consider mobile nanomachines (e.g., a mobile transmitter nanomachine and
a time-evolving diseased biological tissue as a receiver nanomachine), and then, we assume a mobility
model, like Brownian motion, for the transmitter nanomachine. Furthermore, we plan to validate this
model through some initial in vitro experiments that will allow us to follow the progression in terms of
both the amount of errors and the specific type of error that occur. In vitro studies based on fractionated
blood products have been used to evaluate the effect of NP on the circulating blood. Since the effect of
a nanoparticulate system on the immunological functions (e.g., macrophages, dendrites, etc.) has been
evaluated, we will rely on these results in order to infer complementary information, namely how the
immune system impacts the effectiveness and concentration of nanoparticles.
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